CGH
BTAI icon

Crossmark Global Holdings’s BioXcel Therapeutics BTAI Stock Holding History

Crossmark Global Holdings’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-799
Closed -$38K – 1329
2023
Q4 		$38K Sell
799
-1
-0.1% -$56 ﹤0.01% 1296
2023
Q3 		$43K Buy
800
+10
+1% +$1.01K ﹤0.01% 1258
2023
Q2 		$121K Buy
790
+2
+0.3% +$666 ﹤0.01% 1281
2023
Q1 		$235K Buy
788
+1
+0.1% +$427 0.01% 1156
2022
Q4 		$270K Buy
787
+8
+1% +$1.93K 0.01% 1057
2022
Q3 		$147K Buy
779
+24
+3% +$5.57K ﹤0.01% 1200
2022
Q2 		$159K Buy
+755
New +$159K ﹤0.01% 1234

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Crossmark Global Holdings's BTAI Position: Q1 2024 in Review

Crossmark Global Holdings sold out of BioXcel Therapeutics (BTAI) in Q1 2024, closing a stake of 799 shares — an estimated $38K sold.

Crossmark Global Holdings first reported a position in BTAI in Q2 2022 and held it in 7 quarters. The position peaked at $270K in Q4 2022. 73 funds tracked by Wall St. Rank hold BTAI as of Q1 2024.

  • Crossmark Global Holdings reported no remaining BioXcel Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Crossmark Global Holdings sold 799 BioXcel Therapeutics shares in Q1 2024, an estimated $38K.
  • Crossmark Global Holdings first reported a position in BioXcel Therapeutics in Q2 2022 and held it in 7 quarters.
  • Crossmark Global Holdings's BioXcel Therapeutics position peaked at $270K in Q4 2022.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2024.

Based on Crossmark Global Holdings's 13F filing for Q1 2024, filed 13 May 2024.